64 completed, 28 terminated, 8 withdrawn, 5 active not recruiting. 76 Phase 2, 36 Phase 1, 5 Not applicable, 2 Early Phase 1, 2 Phase 3.
Follow Stage IV Melanoma: new trials by email Literature Review of Stage IV Melanoma trials Research Report on Stage IV Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial Psilocybin (high dose), Psilocybin (low dose), PEARL Therapy - Advanced Cancer, Stage IV Solid Tumor Cancer | Phase 2 | Not yet recruiting | University Health Network, Toronto | 46 | 2026-09-14 | 2026-10-15 |
| Investigating Participation Patterns Among Stage IV Melanoma Patients Stage IV Melanoma | Not yet recruiting | Power Life Sciences Inc. | 500 | 2024-11-01 | 2023-10-23 | |
| Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer Psilocybin - Advanced Cancer, Stage IV Solid Tumor Cancer | Phase 2 | Active not recruiting | University Health Network, Toronto | 15 | 2024-06-06 | 2026-06-22 |
| Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients Cyclophosphamide, Fludarabine, Lifileucel - Locally Advanced Melanoma, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Phase 1 | Active not recruiting | Richard Wu | 2 | 2022-07-01 | 2026-02-24 |
| Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS) Pembrolizumab - Melanoma Metastatic, Melanoma Recurrent | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 29 | 2021-12-10 | 2026-01-29 |
| Sargramostim (GM-CSF) + PD-1 Sargramostim (GM-CSF), Pembrolizumab (anti-PD-1) - Unresectable Melanoma, Metastatic Melanoma | Phase 2 | Withdrawn | Dana-Farber Cancer Institute | 2021-04-16 | 2023-05-22 | |
| Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer Educational Video and QPL List, Usual Care - Stage IV Melanoma, Advanced Lung Cancer | Not applicable | Completed | Massachusetts General Hospital | 199 | 2021-01-23 | 2026-08-25 |
| A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma Atezolizumab, Bevacizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Stage IV Melanoma | Phase 2 | Active not recruiting | F. Stephen Hodi, MD | 30 | 2020-08-06 | 2026-08-05 |
| Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors ImmunicomAIAC - Stage IV Non-small Cell Lung Cancer, Stage IV Melanoma | Phase 1 | Unknown | Dr. Ronnie Shapira | 30 | 2020-02-24 | 2021-03-24 |
| Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors TBX-3400 - Stage III Melanoma, Stage IV Melanoma | Phase 1 | Unknown | Taiga Biotechnologies, Inc. | 72 | 2019-06-02 | 2022-05-03 |
| TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma Trametinib, Dabrafenib - Stage IV Melanoma, Stage III Melanoma | Phase 2 | Completed | Universitair Ziekenhuis Brussel | 45 | 2019-01-28 | 2023-09-26 |
| Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib Nivolumab + Ipilimumab, Encorafenib + Binimetinib - Unresectable Stage III Melanoma, Stage IV Melanoma | Phase 2 | Active not recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 271 | 2018-10-30 | 2025-08-01 |
| Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma Pembrolizumab with All-Trans Retinoic Acid - Stage IV Melanoma, Stage III Melanoma | Phase 1 / Phase 2 | Completed | University of Colorado, Denver | 26 | 2017-10-31 | 2024-10-01 |
| Radiation Use During Vemurafenib Treatment Radiation therapy, Vemurafenib - BRAFV600 Mutation, Stage IV Melanoma | Phase 1 | Withdrawn | University of Utah | 2017-06-01 | 2017-05-24 | |
| A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma A-dmDT390-bisFv(UCHT1), Pembrolizumab, Ionizing Radiation - Stage IV Melanoma | Phase 1 / Phase 2 | Unknown | Virogen Biotechnology Inc. | 63 | 2017-01-01 | 2016-12-13 |
| Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients Stage IV Melanoma | Terminated | Mayo Clinic | 17 | 2016-04-01 | 2019-11-07 | |
| Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma IMP321 (eftilagimod alpha), Pembrolizumab - Stage IV Melanoma, Stage III Melanoma | Phase 1 | Completed | Immutep Australia Pty. Ltd. | 24 | 2016-04-01 | 2019-12-18 |
| Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma lymph node, X-ACT - Stage IIIC Skin Melanoma, Stage IV Melanoma | Phase 1 | Terminated | Case Comprehensive Cancer Center | 3 | 2015-03-17 | 2018-12-06 |
| Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma Pembrolizumab - Unresectable Malignant Neoplasm, Melanoma | Phase 2 | Completed | St. Louis University | 10 | 2015-01-01 | 2019-06-20 |
| Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations Raf kinase inhibitor LGX818, binimetinib, laboratory biomarker analysis - Recurrent Melanoma, Stage IV Melanoma | Phase 2 | Withdrawn | Jonsson Comprehensive Cancer Center | 2015-01-01 | 2020-07-27 |
Showing 20 of 111. Sign in to see all of them.
Melanoma (111) · Carcinoma, Renal Cell (9) · Uveal Melanoma (8) · Neoplasms (7) · Skin Neoplasms (7) · Brain Neoplasms (6) · Breast Neoplasms (6) · Breast Neoplasms, Male (5) · Carcinoma, Non-Small-Cell Lung (5) · Carcinoma, Ovarian Epithelial (3) · Colonic Neoplasms (3) · Carcinoma, Basal Cell (2) · Carcinoma, Merkel Cell (2) · Endocrine Gland Neoplasms (2) · Lymphoma (2)
Neoplasms by Histologic Type (111) · Neoplasms by Site (111) · Neoplasms, Germ Cell and Embryonal (111) · Neoplasms, Nerve Tissue (111) · Neuroectodermal Tumors (111) · Neuroendocrine Tumors (111) · Nevi and Melanomas (111) · Skin Diseases (111) · Skin and Connective Tissue Diseases (111) · Neoplasms (104) · Skin Neoplasms (104) · Neoplasms, Glandular and Epithelial (13) · Urogenital Diseases (13) · Urogenital Neoplasms (13) · Carcinoma (12)
Interleukin-2 (11) · aldesleukin (10) · pembrolizumab (9) · Cyclophosphamide (8) · Ipilimumab (8) · Biopsy (7) · Immunohistochemistry (7) · montanide ISA 51 (6) · Polymerase Chain Reaction (5) · Sirolimus (5) · temsirolimus (5) · CTLA-4 Antigen (4) · Dacarbazine (4) · MART-1 Antigen (4) · Nivolumab (4)
National Cancer Institute (NCI) (43) · Fred Hutchinson Cancer Center (5) · Mayo Clinic (4) · Case Comprehensive Cancer Center (3) · Eisai Inc. (3) · Vanderbilt-Ingram Cancer Center (3) · Abramson Cancer Center at Penn Medicine (2) · NewLink Genetics Corporation (2) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (2) · University Health Network, Toronto (2) · Vical (2) · Abbott (1) · Albert Einstein College of Medicine (1) · Assistance Publique - Hôpitaux de Paris (1) · Burzynski Research Institute (1)
United States (96) · Canada (4) · Australia (3) · Germany (3) · United Kingdom (3) · France (2) · Italy (2) · Spain (2) · Austria (1) · Belgium (1) · Brazil (1) · Denmark (1) · Finland (1) · Israel (1) · Netherlands (1)
Thomas Gajewski (4) · Anna Pavlick (3) · Cassian Yee (3) · Jeffrey Weber (3) · Kevin Kim (3) · Svetomir Markovic (3) · Ernest C. Borden, MD (2) · Frank Hodi (2) · Kim Margolin (2) · Patrick Hwu (2) · Sylvia Lee (2) · Wenyin Shi, MD, PhD (2) · Ahmad Tarhini (1) · Andres Forero, MD (1) · Antoni Ribas (1)
PMID 20098694, PMID 20967484, PMID 21206909, PMID 21642685, PMID 23228035, PMID 24464266, PMID 25250858, PMID 25795722, PMID 26837440, PMID 27269940, PMID 28508253, PMID 28754534, PMID 28816150, PMID 29943192, PMID 31998643, PMID 32641862, PMID 32692450, PMID 33861486, PMID 39374099, PMID 39938469, PMID 40449497, PMID 41152967
U10CA031946 (4), K12CA076930 (3), N01CM62202 (3), N01CM62204 (3), U01CA062490 (3), N01CM62201 (2), N01CM62203 (2), N01CM62206 (2), P30CA006516 (2), P30CA043703 (2), P30CA068485 (2), U10CA032102 (2), 2015 (1), 2017 (1), N01CM00070 (1)